Abstract: The present invention relates to compositions comprising clofazimine and methods for treating cancer. In various embodiments, the compositions and methods further comprise a proteasome inhibitor and/or immunomodulatory drug. The compositions and methods of the present invention may be used for naïve cancers as well as those that have developed resistance to proteasome inhibitors and/or immunomodulatory drugs.

Abstract: A method to predict the response. e.g., a strong positive response or a strong lack of responsive, of myeloma cells of a multiple myeloma patient to a proteasome inhibitor is provided.